Skip to main content
SpringerLink
Log in

Adherence to alendronate in male veterans

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

In one Veterans Affairs’ medical center, alendronate non-adherence was more likely in male veterans who smoke or report side effects, and less likely in men undergoing bone densitometry during therapy. Providers urgently need programs to increase adherence to osteoporosis medications. Initial programs should target patients with risk factors for non-adherence.

Introduction

Adherence to osteoporosis therapy in men is unknown. We hypothesized that ca. 50% of men at one center would be adherent to alendronate and one or more patient-specific factors would associate with adherence.

Methods

We conducted a retrospective chart review study of male veterans to determine the rates and predictors of alendronate adherence over two years. We excluded women, men who received primary care elsewhere and those who took alendronate for indications other than low bone mass. We defined adherence as a medication possession ratio ≥80% in the first 24 months of therapy.

Results

Adherence in the first 12 and 24 months of therapy was 59% and 54%, respectively. In multivariate analyses, non-adherence was more likely in men using tobacco (OR 2.08, 95% CI 1.13, 3.84, p = 0.02) and reporting side effects (OR 2.06, 95% CI 1.14, 3.73, p = 0.02) and less likely in men undergoing bone density during therapy (OR 0.49, 95% CI 0.26, 0.90, p = 0.02).

Conclusions

Alendronate non-adherence is more likely in male veterans who smoke or report side effects, and less likely in men having bone densitometry during therapy. Providers urgently need programs to increase adherence to osteoporosis medications. Initial programs should target patients with risk factors for non-adherence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Woolf AD, Pfleger B (2003) Burden of major musculoskeletal conditions. Bull World Health Organ 81:646–656

    PubMed  Google Scholar 

  2. (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795

  3. (2003) Physician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation: Washington, DC

  4. Binkley N, Krueger D (2002) Osteoporosis in men. WMJ 101:28–32

    PubMed  Google Scholar 

  5. Compston J (2001) Secondary causes of osteoporosis in men. Calcif Tissue Int 69:193–195

    Article  PubMed  CAS  Google Scholar 

  6. Kelepouris N, Harper KD, Gannon F et al (1995) Severe osteoporosis in men. Ann Intern Med 123:452–460

    PubMed  CAS  Google Scholar 

  7. Riggs BL, Khosla S, Melton LJ 3rd (1998) A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13:763–773

    Article  PubMed  CAS  Google Scholar 

  8. Orwoll E, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604–610

    Article  PubMed  CAS  Google Scholar 

  9. Adachi JD, Saag KG, Delmas PD et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211

    Article  PubMed  CAS  Google Scholar 

  10. Wallach S, Cohen S, Reid DM et al (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277–285

    Article  PubMed  CAS  Google Scholar 

  11. Finkelstein JS, Hayes A, Hunzelman JL et al (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216–1226

    Article  PubMed  CAS  Google Scholar 

  12. Orwoll ES, Scheele WH, Paul S et al (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17

    Article  PubMed  CAS  Google Scholar 

  13. Badamgarav E, Fitzpatrick LA (2006) A new look at osteoporosis outcomes: the influence of treatment, compliance, persistence, and adherence. Mayo Clin Proc 81:1009–1012

    PubMed  Google Scholar 

  14. Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003–1008

    Article  PubMed  Google Scholar 

  15. McCombs JS, Thiebaud P, McLaughlin-Miley C et al (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287

    Article  PubMed  CAS  Google Scholar 

  16. Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022

    PubMed  Google Scholar 

  17. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928

    Article  PubMed  Google Scholar 

  18. Weycker D, Macarios D, Edelsberg J et al (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645–1652

    Article  PubMed  CAS  Google Scholar 

  19. Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856–861

    PubMed  Google Scholar 

  20. Solomon DH, Avorn J, Katz JN et al (2005) Compliance with osteoporosis medications. Arch Intern Med 165:2414–2419

    Article  PubMed  Google Scholar 

  21. Yood RA, Emani S, Reed JI et al (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965–968

    Article  PubMed  CAS  Google Scholar 

  22. Papaioannou A, Ioannidis G, Adachi JD et al (2003) Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14:808–813

    Article  PubMed  CAS  Google Scholar 

  23. Curtis, JR, Westfall AO, Allison JJ et al (2006) Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int 17:1268–1274

    Article  PubMed  CAS  Google Scholar 

  24. Cooper A, Drake J, Brankin E (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60:896–905

    Article  PubMed  CAS  Google Scholar 

  25. Rossini M, Bianchi G, Di Munno O et al (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914–921

    Article  PubMed  CAS  Google Scholar 

  26. Gold DT, Alexander IM, Ettinger MP (2006) How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy. Ann Pharmacother 40:1143–1150

    Article  PubMed  CAS  Google Scholar 

  27. Lo JC, Pressman AR, Omar MA et al (2006) Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 17:922–928

    Article  PubMed  CAS  Google Scholar 

  28. Downey TW, Foltz SH, Boccuzzi SJ et al (2006) Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 99:570–575

    Article  PubMed  Google Scholar 

  29. Ensrud KE, Barrett-Connor EL, Schwartz A et al (2004) Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 19:1259–1269

    Article  PubMed  CAS  Google Scholar 

  30. Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938

    Article  PubMed  CAS  Google Scholar 

  31. Fisher L, Belle GV (1993) Biostatistics: a methodology for the health sciences. Wiley, New York

    Google Scholar 

  32. Vik SA, Hogan DB, Patten SB et al (2006) Medication nonadherence and subsequent risk of hospitalisation and mortality among older adults. Drugs Aging 23:345–356

    Article  PubMed  Google Scholar 

  33. Barr RG, Somers SC, Speizer FE et al (2002) Patient factors and medication guideline adherence among older women with asthma. Arch Intern Med 162:1761–1768

    Article  PubMed  Google Scholar 

  34. Lavigne M, Rocher I, Steensma C et al (2006) The impact of smoking on adherence to treatment for latent tuberculosis infection. BMC Public Health 6:66

    Article  PubMed  Google Scholar 

  35. Law MR, Hackshaw AK (1997) A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ 315:841–846

    PubMed  CAS  Google Scholar 

  36. Solomon DH, Avorn J (2003) Pharmacoepidemiology and rheumatic diseases: 2001–2002. Curr Opin Rheumatol 15:122–126

    Article  PubMed  Google Scholar 

  37. Morris AB, Li J, Kroenke K et al (2006) Factors associated with drug adherence and blood pressure control in patients with hypertension. Pharmacotherapy 26:483–492

    Article  PubMed  Google Scholar 

  38. Benner JS, Glynn RJ, Mogun H et al (2002) Long-term persistence in use of statin therapy in elderly patients. JAMA 288:455–461

    Article  PubMed  Google Scholar 

  39. Carr AJ, Thompson PW, Cooper C (2006) Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 17:1638–1644

    Article  PubMed  CAS  Google Scholar 

  40. Miller PD, Woodson G, Licata AA et al (2000) Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther 22:1433–1442

    Article  PubMed  CAS  Google Scholar 

  41. Compston JE, Seeman E (2006) Compliance with osteoporosis therapy is the weakest link. Lancet 368:973–974

    Article  PubMed  Google Scholar 

  42. Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117–1123

    Article  PubMed  CAS  Google Scholar 

  43. Wu JY, Leung WY, Chang S et al (2006) Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial. BMJ 333:522

    Article  PubMed  Google Scholar 

  44. Raynor DK, Booth TG, Blenkinsopp A (1993) Effects of computer generated reminder charts on patients’ compliance with drug regimens. BMJ 306:1158–1161

    Article  PubMed  CAS  Google Scholar 

  45. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

    K. E. Hansen, E. D. Swenson & A. N. Jones

  2. University of Wisconsin Osteoporosis Clinical Center & Research Program, Madison, WI, USA

    K. E. Hansen & A. N. Jones

  3. University of Wisconsin School of Pharmacy, Madison, WI, USA

    B. Baltz & M. E. Elliott

  4. William S. Middleton Veterans Affairs Medical Center, Madison, WI, USA

    A. A. Schuna & M. E. Elliott

  5. Department of Medicine, UW School of Medicine and Public Health, Mailbox 3244, Clinical Science Center, 600 Highland Avenue, Madison, WI, 53792, USA

    K. E. Hansen

Authors
  1. K. E. Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. D. Swenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Baltz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. A. Schuna
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. N. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. E. Elliott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. E. Hansen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hansen, K.E., Swenson, E.D., Baltz, B. et al. Adherence to alendronate in male veterans. Osteoporos Int 19, 349–356 (2008). https://doi.org/10.1007/s00198-007-0471-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-007-0471-4

Keywords

Search

Navigation